Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

NCT07218783 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Cataract
Glaucoma
Ocular Hypertension

Interventions

DRUG: Bimatoprost Implant System
DEVICE: SpyGlass IOL
DRUG: Timolol Maleate Ophthalmic Solution, 0.5%
DEVICE: Commercial IOL

Sponsor

SpyGlass Pharma, Inc.